These studies highlight that metformin activates intestinal AMPK to improve glucose tolerance and lower body weight together with its lowering effect on hepatic glucose production6,9, and chronic inhibition of intestinal AMPK is sufficient to dysregulate glucose homeostasis and induce obesity (Fig. 1). The gene discussed is PRKAA2; the disease is obesity disorder.